How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-methylene-blue-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous methylene blue administration — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous methylene blue administration (Intravenous methylene blue administration) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Redox agent / Monoamine oxidase inhibitor. Area: Neurology / Psychiatry / Critical Care.

phase 3 Redox agent / Monoamine oxidase inhibitor Mitochondrial electron transport chain; Monoamine oxidase Neurology / Psychiatry / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous methylene blue administration (Intravenous methylene blue administration) — Seoul National University Hospital. Methylene blue acts as a redox agent and monoamine oxidase inhibitor that reduces oxidative stress and modulates mitochondrial function.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous methylene blue administration TARGET	Intravenous methylene blue administration	Seoul National University Hospital	phase 3	Redox agent / Monoamine oxidase inhibitor	Mitochondrial electron transport chain; Monoamine oxidase
Methylene blue (1%)	Methylene blue (1%)	University Hospital, Strasbourg, France	marketed	Redox agent; monoamine oxidase inhibitor	Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Redox agent / Monoamine oxidase inhibitor class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous methylene blue administration — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-methylene-blue-administration. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab